Cargando…

The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study

Mastocytosis patients often experience a number of symptoms, including mastocytosis-associated pain that is difficult to manage due to resistance to usual antalgic treatments and/or the patient’s poor tolerance. Mastocytosis patients display significantly higher levels of indoleamine-2,3-dioxygenase...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossignol, Julien, Hatton, Séverine, Ridley, Ashley, Hermine, Olivier, Greco, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953706/
https://www.ncbi.nlm.nih.gov/pubmed/36831056
http://dx.doi.org/10.3390/biomedicines11020520
_version_ 1784893944580014080
author Rossignol, Julien
Hatton, Séverine
Ridley, Ashley
Hermine, Olivier
Greco, Céline
author_facet Rossignol, Julien
Hatton, Séverine
Ridley, Ashley
Hermine, Olivier
Greco, Céline
author_sort Rossignol, Julien
collection PubMed
description Mastocytosis patients often experience a number of symptoms, including mastocytosis-associated pain that is difficult to manage due to resistance to usual antalgic treatments and/or the patient’s poor tolerance. Mastocytosis patients display significantly higher levels of indoleamine-2,3-dioxygenase-1 (IDO1) activity, leading to hyperactivation of the N-methyl-D-aspartate receptor. As cannabidiol (CBD) is known to inhibit IDO1′s enzymatic activity, we hypothesized that pharmaceutical-grade CBD is an effective treatment for mastocytosis-associated pain. Patients with non-advanced mastocytosis and refractory pain were eligible for inclusion in this observational pilot study. CBD was initiated at 50 mg/day and increased to a maximum of 900 mg/day. Pain was scored on a 0-to-10 numerical rating scale (NRS). A total of 44 patients were included over a 2-year period. The median dose of CBD prescribed was 300 mg/day (range: 50–900 mg/day). Elevated liver enzymes were observed in one patient. The mean ± standard deviation NRS pain score decreased significantly from 7.27 ± 1.35 before treatment to 3.78 ± 1.99 after 3 months of treatment (p < 0.0001). Fifteen patients (34%) were able to discontinue all their previous antalgic medications. CBD treatment might be a safe, effective treatment for mastocytosis-associated pain and its use requires confirmation in a randomized, controlled trial.
format Online
Article
Text
id pubmed-9953706
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99537062023-02-25 The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study Rossignol, Julien Hatton, Séverine Ridley, Ashley Hermine, Olivier Greco, Céline Biomedicines Case Report Mastocytosis patients often experience a number of symptoms, including mastocytosis-associated pain that is difficult to manage due to resistance to usual antalgic treatments and/or the patient’s poor tolerance. Mastocytosis patients display significantly higher levels of indoleamine-2,3-dioxygenase-1 (IDO1) activity, leading to hyperactivation of the N-methyl-D-aspartate receptor. As cannabidiol (CBD) is known to inhibit IDO1′s enzymatic activity, we hypothesized that pharmaceutical-grade CBD is an effective treatment for mastocytosis-associated pain. Patients with non-advanced mastocytosis and refractory pain were eligible for inclusion in this observational pilot study. CBD was initiated at 50 mg/day and increased to a maximum of 900 mg/day. Pain was scored on a 0-to-10 numerical rating scale (NRS). A total of 44 patients were included over a 2-year period. The median dose of CBD prescribed was 300 mg/day (range: 50–900 mg/day). Elevated liver enzymes were observed in one patient. The mean ± standard deviation NRS pain score decreased significantly from 7.27 ± 1.35 before treatment to 3.78 ± 1.99 after 3 months of treatment (p < 0.0001). Fifteen patients (34%) were able to discontinue all their previous antalgic medications. CBD treatment might be a safe, effective treatment for mastocytosis-associated pain and its use requires confirmation in a randomized, controlled trial. MDPI 2023-02-10 /pmc/articles/PMC9953706/ /pubmed/36831056 http://dx.doi.org/10.3390/biomedicines11020520 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Rossignol, Julien
Hatton, Séverine
Ridley, Ashley
Hermine, Olivier
Greco, Céline
The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study
title The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study
title_full The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study
title_fullStr The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study
title_full_unstemmed The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study
title_short The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study
title_sort effectiveness and safety of pharmaceutical-grade cannabidiol in the treatment of mastocytosis-associated pain: a pilot study
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953706/
https://www.ncbi.nlm.nih.gov/pubmed/36831056
http://dx.doi.org/10.3390/biomedicines11020520
work_keys_str_mv AT rossignoljulien theeffectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy
AT hattonseverine theeffectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy
AT ridleyashley theeffectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy
AT hermineolivier theeffectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy
AT grecoceline theeffectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy
AT rossignoljulien effectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy
AT hattonseverine effectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy
AT ridleyashley effectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy
AT hermineolivier effectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy
AT grecoceline effectivenessandsafetyofpharmaceuticalgradecannabidiolinthetreatmentofmastocytosisassociatedpainapilotstudy